Oxford Biomedica PLC
06 October 2026
OXB
Admission to Trading Application
Oxford, UK – 06 October 2026:OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces thatapplication has been made to the London Stock Exchange for the admission to trading of 5,654 ordinary shares of 50 pence each in the Company (the “New Ordinary Shares”).
The requested admission relates to ordinary shares which have been allotted under:
- OXB Long Term Incentive Plan (LTIP)
It is expected that admission becomes effective on 09 October 2026. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary
T: +44 (0) 1865 783 000 / E:cosec@oxb.com
About OXB
OXB (LSE: OXB) is aglobalquality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has30years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilitiesrangefrom early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system),adual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, aFTSE250 andFTSE4Good constituent, is headquartered in Oxford, UK. It hasdevelopmentand manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France,BedfordMA,and Durham NC,US. Learn more atwww.oxb.comand follow us onLinkedInandYouTube.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.